Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A response to strategy #2: streamlining the regulatory process.

W Paul Glezen1

  • 1Influenza Research Center, Department of Molecular Virology, Baylor College of Medicine, Houston, TX 77030, USA. wglezen@bcm.tmc.edu

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|February 1, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Editorial commentary: Changing epidemiology of influenza B virus.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2014
Same author

The burden of influenza B: a structured literature review.

American journal of public health·2013
Same author

Picornavirus, the most common respiratory virus causing infection among patients of all ages hospitalized with acute respiratory illness.

Journal of clinical microbiology·2011
Same author

Broadening indications for maternal influenza vaccination.

The Journal of infectious diseases·2011
Same author

Cell-culture-derived influenza vaccine production.

Lancet (London, England)·2011
Same author

How did the 2008-2009 seasonal influenza vaccine affect the pandemic?

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2010
Same journal

Reconsidering ambiguous language in infectious disease consult recommendations.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Antibiotic Treatment Duration for Uncomplicated Monomicrobial Enterococcal Bloodstream Infection: A Multicenter Target Trial Emulation.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Larger Blood Volume Increases Detection of Fastidious Mycobacteria and Fungi in Blood Culture.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Anticalcitonin: Limited utility of a context-dependent biomarker demonstrated in another real-world data set.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Procalcitonin Testing in Community-Acquired Pneumonia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Wanted: A Relevant Correlate of Protection for Dengue Vaccines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
See all related articles

Regulatory hurdles are limiting vaccine production, particularly for influenza vaccines, despite rising vulnerable populations and pandemic risks. Collaboration between regulators and manufacturers is crucial for increasing the supply of safe vaccines.

Area of Science:

  • Vaccinology and Public Health
  • Biopharmaceutical Manufacturing
  • Regulatory Science

Background:

  • The United States faces a significant decline in vaccine production capacity.
  • Influenza virus vaccine supply is critically limited, posing risks to public health.
  • Increasingly vulnerable populations and the persistent threat of pandemics heighten the urgency for robust vaccine manufacturing.

Discussion:

  • Excessive regulatory burden is identified as a primary factor contributing to the reduction in domestic vaccine manufacturing.
  • The current state of vaccine production is insufficient to meet escalating public health demands and pandemic preparedness needs.
  • A critical need exists for regulatory bodies to actively engage with manufacturers to streamline and modernize production processes.

Key Insights:

Related Experiment Videos

  • Regulatory policies significantly impact the viability and expansion of vaccine production facilities.
  • Limited vaccine supply, especially for influenza, creates a precarious public health situation.
  • Proactive regulatory adaptation is essential for ensuring a stable and adequate supply of vaccines.

Outlook:

  • Facilitating the adoption of innovative production practices is key to expanding vaccine supply.
  • Enhanced collaboration between regulatory agencies and vaccine manufacturers can overcome production challenges.
  • Strengthening domestic vaccine production is vital for national health security and pandemic response.